Active substance
Calcium acetate
- US FDA 19
- US price lines 3
- NHS prices 2
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CALCIUM ACETATE | 667MG | capsule · oral | HIKMA PHARMS | Prescription | 26 Feb 2008 |
| CALCIUM ACETATE | 667MG | capsule · oral | CHARTWELL RX | Prescription | 1 Jun 2012 |
| CALCIUM ACETATE | 667MG | tablet · oral | CHARTWELL MOLECULAR | Prescription | 5 Feb 2013 |
| CALCIUM ACETATE | 667MG | capsule · oral | INVAGEN PHARMS | Prescription | 7 Feb 2013 |
| CALCIUM ACETATE | 667MG | tablet · oral | HERITAGE PHARMS INC | Prescription | 22 Jan 2015 |
| CALCIUM ACETATE | 667MG | capsule · oral | HERITAGE PHARMS INC | Prescription | 29 Jun 2015 |
| CALCIUM ACETATE | 667MG | capsule · oral | MPP PHARMA | Prescription | 26 Oct 2015 |
| CALCIUM ACETATE | 667MG | capsule · oral | COHANCE LIFESCIENCES | Prescription | 21 Feb 2020 |
| CALCIUM ACETATE | 667MG | capsule · oral | ADAPTIS | Prescription | 13 Mar 2023 |
| PHOSLO | 667MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | FRESENIUS MEDCL CARE | Discontinued | 10 Dec 1990 |
| PHOSLO | 333.5MG; 667MG | capsule · oral | FRESENIUS MEDCL CARE | Discontinued | 2 Apr 2001 |
| PHOSLO GELCAPS | 667MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | FRESENIUS MEDCL CARE | Discontinued | 2 Apr 2001 |
| CALCIUM ACETATE | 667MG | tablet · oral | HIKMA PHARMS | Discontinued | 30 Jan 2008 |
| ELIPHOS | 667MG | tablet · oral | CYPRESS PHARM | Discontinued | 24 Nov 2008 |
| CALCIUM ACETATE | 667MG | tablet · oral | PADAGIS US | Discontinued | 13 Apr 2011 |
| PHOSLYRA | 667MG/5ML | solution · oral | FRESENIUS MEDCL CARE | Discontinued | 18 Apr 2011 |
| CALCIUM ACETATE | 667MG | capsule · oral | AMNEAL PHARMS | Discontinued | 6 Oct 2014 |
| CALCIUM ACETATE | 667MG | capsule · oral | LUPIN | Discontinued | 9 Jul 2015 |
| CALCIUM ACETATE | 667MG | capsule · oral | LOTUS PHARM CO LTD | Discontinued | 26 Jul 2016 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CALCIUM ACETATE 667 MG CAPSULE | $0.16972 | per EA | 23 Sep 2026 |
| US NADAC | CALCIUM ACETATE 667 MG GELCAP | $0.16972 | per EA | 23 Sep 2026 |
| US NADAC | CALCIUM ACETATE 667 MG TABLET | $0.43873 | per EA | 22 Jul 2026 |
| NHS Drug Tariff | Calcium acetate 475mg tablets | £16.95 | 200 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Calcium acetate 950mg tablets | £23.75 | 200 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 30 Sep 2020 PHOSLYRA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.